Processa Pharmaceuticals PCSA Income Statement (2012-2026)

NASDAQ PCSA
$1.99 -0.17 (-7.87%)
At close: Sep 9, 2026 · 4:00 PM EDT
Reported Financials

Processa Pharmaceuticals Quarterly Income Statement

Periods 57 quarters
Latest Jun 2026

Processa Pharmaceuticals reported net income of -$3.27M for the quarter ended Jun 2026. This income statement covers 57 quarters of results from Jun 2012 through Jun 2026, standardized by Business Quant from the company’s SEC filings.

Income Statement Jun2012 Sep2012 Dec2012 Mar2013 Jun2013 Sep2013 Dec2013 Mar2014 Jun2014 Sep2014 Dec2014 Mar2015 Jun2015 Sep2015 Dec2015 Mar2016 Jun2016 Sep2016 Dec2016 Mar2017 Jun2017 Sep2017 Dec2017 Mar2018 Jun2018 Sep2018 Dec2018 Mar2019 Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025 Dec2025 Mar2026 Jun2026
Shares Outstanding (Entity)Shares Outstanding (Entity.)
0.03M0.03M0.03M0.03M0.03M0.03M0.05M0.05M0.05M0.05M0.11M0.11M0.13M0.12M0.38M0.62M2.11M1.31M2.68M2.79M
Revenue & cost
Revenue
Gross Profit
Operating items
Research & DevelopmentR&D
1.72M2.07M2.04M3.14M3.14M3.17M1.63M1.69M1.15M1.32M1.54M1.73M2.29M1.71M1.59M2.45M1.66M2.11M1.81M0.65M
Selling, General & AdministrativeSG&A
1.34M1.30M1.18M2.03M2.92M2.63M2.48M1.03M1.02M1.15M1.27M1.35M1.14M1.02M1.26M1.50M1.83M1.59M1.52M1.69M
Restructuring CostsRestructuring
0.67M0.63M0.68M0.59M
Other Operating ExpensesOther Opex
Operating ExpensesOpex
3.06M3.37M3.23M5.17M6.06M5.80M4.11M2.71M2.17M2.47M2.81M3.08M3.42M2.73M3.52M4.58M3.49M3.70M4.01M2.92M
Operating IncomeOp. Inc
-3.11M-3.37M-3.23M-5.17M-6.06M-13.07M-4.11M-2.71M-2.17M-2.47M-2.81M-3.08M-3.42M-2.73M-2.85M-3.95M-3.49M-3.70M-3.33M-2.34M
EBIT
-3.11M-3.37M-3.23M-5.17M-6.06M-13.07M-4.11M-2.71M-2.17M-2.47M-2.81M-3.08M-3.42M-2.73M-2.85M-3.95M-3.49M-3.70M-3.33M-2.34M
Non-operating items
Non Operating Interest Expenses
Interest & Investment IncomeInt & Inv Inc
0.00M0.00M0.00M0.01M0.04M0.06M0.09M0.06M-0.08M0.04M0.24M0.01M0.01M0.01M-0.00M
Other Non Operating IncomeOther Non Op Inc.
0.00M0.01M0.08M0.10M0.08M0.07M0.04M-0.12M0.01M0.01M0.05M0.07M-0.05M-0.93M
Non Operating IncomeNon Op. Inc.
0.02M-0.93M
Net income details
EBT
-3.11M-3.37M-3.23M-5.16M-6.02M-13.01M-4.02M-2.61M-2.08M-2.40M-2.89M-3.01M-3.38M-2.50M-2.83M-3.94M-3.49M-3.70M-3.38M-2.34M
Tax ProvisionsTaxes
-0.12M-0.18M
Profit After TaxPAT
-2.99M-3.18M-3.23M-5.16M-6.02M-13.01M-4.02M-2.61M-2.08M-2.40M-2.73M-3.01M-3.38M-2.73M-2.83M-3.93M-3.44M-3.40M-3.38M-3.27M
Income from Continuing OperationsIncome (Continuing)
-2.99M-3.18M-3.23M-5.16M-6.02M-13.01M-4.02M-2.61M-2.08M-2.40M-2.89M-3.01M-3.38M-2.50M-2.83M-3.94M-3.49M-3.70M-3.38M-2.34M
Income from Discontinued OperationsIncome (Discontinued)
Consolidated Net IncomeConsol Net Inc.
-2.99M-3.18M-3.23M-5.16M-6.02M-13.01M-4.02M-2.61M-2.08M-2.40M-2.89M-3.01M-3.38M-2.50M-2.83M-3.94M-3.49M-3.70M-3.38M-2.34M
Income towards Parent CompanyParent Net Inc
-2.99M-3.18M-3.23M-5.16M-6.02M-13.01M-4.02M-2.61M-2.08M-2.40M-2.89M-3.01M-3.38M-2.50M-2.83M-3.94M-3.49M-3.70M-3.38M-2.34M
Preferred Dividend PaymentsPref Dividends
Net Income towards Common StockholdersNet Income
-2.99M-3.18M-3.23M-5.16M-6.02M-13.01M-4.02M-2.61M-2.08M-2.40M-2.73M-3.01M-3.38M-2.73M-2.83M-3.93M-3.44M-3.36M-3.38M-3.27M
Additional items
EPS (Basic)
-96.17-103.91-101.92-161.99-185.82-403.87-88.32-48.50-38.55-45.84-27.63-25.23-25.83-22.29-7.44-6.32-1.81-2.57-1.29-1.19
EPS (Diluted)
-320.76-341.87-346.52-161.99-185.82-403.87-88.31-48.50-38.55-45.84-27.63-25.23-25.83-22.29-7.44-6.32-3.46-2.57-1.29-1.19
Shares Outstanding
0.03M0.03M0.03M0.03M0.03M0.03M0.05M0.05M0.05M0.05M0.10M0.12M0.13M0.12M0.38M0.62M1.90M1.31M2.62M2.75M
Shares Outstanding (Diluted)Shares Outstanding (Dil.)
0.01M0.01M0.01M0.03M0.03M0.03M0.05M0.05M0.05M0.05M0.10M0.12M0.13M0.12M0.38M0.62M0.99M1.31M2.62M2.75M
EBITDA
-3.11M-3.37M-3.23M-5.17M-6.06M-13.07M-4.11M-2.71M-2.17M-2.47M-2.81M-3.08M-3.42M-2.73M-2.85M-3.95M-3.49M-3.70M-3.33M-2.34M
Interest ExpensesInt Expense
Tax Rate
3.945.40